Because most diagnosed are young children between 5-9 years of age, and die within a year, and the symptoms of DIPG can be torturously limiting, H. Res. 114 gives a voice to the voiceless. Even with hopeful advocacy, the decades of darkness and silence overshadow the urgent cries for support this disease continues to destroy. The Congressional Briefing has been a opportunity for families, philanthropic leaders, industry leaders, and world renown experts to speak to the reality of DIPG and the unparalleled value of the much underfunded research for pediatric brain cancer, and the doors that DIPG awareness can open not only for science but for HOPE to thousands of children with brain cancer, the #1 disease-related cause of death for children in America. This is our Moonshot4Kids!
#Moonshot4Kids Congressional Briefing & Summit
“H. Res. 114 is a plea to you, our Representatives in Congress, for help; it challenges the world to be aware of this deadly killer of children and know DIPG by name, and to inspire the collaboration of resources toward its cure. With a simple signature, you have the power to attach “hope” to pediatric brain cancer. We hope with all our hearts and minds, that you do.”
Feb. 13, 2020, Washington D. C.
DIPG, Pediatric Brain Cancer, and the Importance of H. Res. 114
Takeaway important quotes, “To Members of Congress”
11am, Rayburn House Office Building, “The Gold Room” (2168) 45, Independence Avenue SW, Washington DC 20515
Pre-Event News Article with Details
And SUMMIT: “The State of DIPG
2pm, Covington & Burling, LLP 850 10th Street NW, Washington, DC 20001
#Moonshot4Kids #KidsLivesMatter #NEGLECTEDnotRare #DIPGwontWait
*Inviting Members of Congress, and alerting Health Subcommittee of Energy and Commerce, House Leadership: Speaker of the House, Chairman of Energy and Commerce, Chairwoman of Health Subcommittee